HRP20151312T1 - Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom - Google Patents
Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom Download PDFInfo
- Publication number
- HRP20151312T1 HRP20151312T1 HRP20151312TT HRP20151312T HRP20151312T1 HR P20151312 T1 HRP20151312 T1 HR P20151312T1 HR P20151312T T HRP20151312T T HR P20151312TT HR P20151312 T HRP20151312 T HR P20151312T HR P20151312 T1 HRP20151312 T1 HR P20151312T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmacological agent
- seq
- mast cell
- cell degranulation
- use according
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 12
- 229940121363 anti-inflammatory agent Drugs 0.000 title 1
- 239000002260 anti-inflammatory agent Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000011260 co-administration Methods 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 claims 18
- 210000003630 histaminocyte Anatomy 0.000 claims 12
- 101710149951 Protein Tat Proteins 0.000 claims 9
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 8
- 230000001387 anti-histamine Effects 0.000 claims 8
- 239000000739 antihistaminic agent Substances 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000028709 inflammatory response Effects 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 claims 2
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 claims 2
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 108700019745 Disks Large Homolog 4 Proteins 0.000 claims 1
- 102000047174 Disks Large Homolog 4 Human genes 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 101150069842 dlg4 gene Proteins 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (13)
1. Farmakološko sredstvo vezano na tat peptid za uporabu za liječenje ili profilaksu bolesti naznačeno time da se inhibitor degranulacije mastocita ili antihistaminik koji inhibira upalni odgovor zbog degranulacije mastocita koji su inducibilni s tat peptidom, daje zajedno s farmakološkim sredstvom.
2. Farmakološko sredstvo za uporabu prema zahtjevu 1, naznačeno time da se inhibitor degranulacije mastocita ili antihistaminik daje prije farmakološkog sredstva.
3. Farmakološko sredstvo za uporabu prema zahtjevu 1, naznačeno time da se inhibitor degranulacije mastocita ili antihistaminik daje istovremeno kao i farmakološko sredstvo.
4. Farmakološko sredstvo za uporabu prema bilo kojem zahtjevu od 1 do 3, naznačeno time da tat peptid ima sekvencu amino kiseline koja sadrži RKKRRQRRR (SEQ ID NO: 51), GRKKRRQRRR (SEQ ID br. 1), YGRKKRRQRRR (SEQ ID br. 2), FGRKKRRQRRR (SEQ ID br. 3) ili GRKKRRQRRRP (SEQ ID br. 4).
5. Farmakološko sredstvo za uporabu prema bilo kojem zahtjevu od 1 do 3, naznačeno time da farmakološko sredstvo je peptid koji ima sekvencu amino kiseline KLSSIESDV (SEQ ID br. 5) ili KLSSIETDV (SEQ ID br. 43).
6. Farmakološko sredstvo za uporabu prema bilo kojem zahtjevu od 1 do 3, naznačeno time da se inhibitor degranulacije mastocita ili antihistaminik daju intravenozno, oralno ili topikalno.
7. Inhibitor degranulacije mastocita ili antihistaminik naznačen time da je za uporabu za inhibiranje upalnog odgovora zbog degranulacije mastocita koji su inducibilni s farmakološkim sredstvom vezanim na tat peptid.
8. Komplet naznačen time da sadrži farmakološko sredstvo vezano na tat peptid, te inhibitor degranulacije mastocita ili antihistaminik koji inhibira upalni odgovor zbog degranulacije mastocita koji su inducibilni s tat peptidom.
9. Farmakološko sredstvo koje inhibira vezanje PSD95 do NDMAR 2B, koji je peptid koji ima sekvencu amino kiseline [E/D/N/Q]-[S/T]-[D/E/Q/N]-[V/L] (SEQ ID br. 38) na njegovom C-završetku, vezanu na tat peptid za uporabu za liječenje ili za utjecanje na profilaksu moždanog udara, epilepsije, hipoksije, traumatske ozljede središnjeg živčanog sustava koja nije povezana sa kapi, Alzheimerove ili Parkinsonove bolesti u kombinaciji s inhibitorom degranulacije mastocita ili antihistaminikom, pri čemu inhibitor degranulacije mastocita ili antihistaminik inhibira upalni odgovor zbog degranulacije mastocita koji su inducibilni s tat peptidom.
10. Farmakološko sredstvo za uporabu prema zahtjevu 9, naznačeno time da tat peptid ima sekvencu amino kiseline koja sadrži RKKRRQRRR (SEQ ID br. 51), GRKKRRQRRR (SEQ ID br. 1), YGRKKRRQRRR (SEQ ID br. 2), FGRKKRRQRRR (SEQ ID br. 3) ili GRKKRRQRRRP (SEQ ID br. 4).
11. Farmakološko sredstvo za uporabu prema zahtjevu 9, naznačeno time da subjekt je žena.
12. Farmakološko sredstvo za uporabu prema zahtjevu 9, naznačeno time da uporaba je profilaksa subjekta koji je u opasnosti od prolaznog cerebralnog ishemijskog udara ili kapi kao rezultata podvrgavanja operaciji srca.
13. Farmakološko sredstvo za uporabu prema zahtjevu 9, naznačeno time da farmakološko sredstvo je peptid koji ima sekvencu amino kiseline KLSSIESDV (SEQ ID br. 5) ili KLSSIETDV (SEQ ID br. 43).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99267807P | 2007-12-05 | 2007-12-05 | |
| PCT/US2008/085280 WO2009076105A2 (en) | 2007-12-05 | 2008-12-02 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| EP08859906.3A EP2229185B8 (en) | 2007-12-05 | 2008-12-02 | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151312T1 true HRP20151312T1 (hr) | 2016-03-11 |
Family
ID=40756064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151312TT HRP20151312T1 (hr) | 2007-12-05 | 2015-12-02 | Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8080518B2 (hr) |
| EP (1) | EP2229185B8 (hr) |
| JP (1) | JP5520230B2 (hr) |
| CN (1) | CN101970011B (hr) |
| AU (1) | AU2008335490B2 (hr) |
| BR (1) | BRPI0820912B1 (hr) |
| DK (1) | DK2229185T3 (hr) |
| ES (1) | ES2555524T3 (hr) |
| HR (1) | HRP20151312T1 (hr) |
| HU (1) | HUE027216T2 (hr) |
| PL (1) | PL2229185T3 (hr) |
| PT (1) | PT2229185E (hr) |
| SI (1) | SI2229185T1 (hr) |
| WO (1) | WO2009076105A2 (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7510824B2 (en) | 1999-06-02 | 2009-03-31 | Nono Inc. | Method of screening peptides useful in treating traumatic injury to the brain or spinal cord |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| WO2008008348A2 (en) * | 2006-07-11 | 2008-01-17 | Arbor Vita Corporation | Method and compositions for treating stroke with fever |
| US8008253B2 (en) | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| JP6005357B2 (ja) * | 2008-05-16 | 2016-10-12 | ノノ インコーポレイテッド | てんかんの治療 |
| CA2739416C (en) | 2008-09-03 | 2017-10-31 | Arbor Vita Corporation | Agents and methods for treatment of pain |
| JP6005514B2 (ja) | 2009-06-10 | 2016-10-12 | ノノ インコーポレイテッド | 神経疾患の治療のためのモデル系及び治療計画 |
| EP3682895A1 (en) * | 2009-06-10 | 2020-07-22 | NoNO Inc. | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
| US9301999B2 (en) | 2009-09-28 | 2016-04-05 | Duke University | Peptide, adjuvants, vaccines, and methods of use |
| EP2552472A4 (en) * | 2010-03-29 | 2014-03-12 | Massachusetts Inst Technology | ANTI-INFLAMMATORY FACTORS |
| WO2012009075A1 (en) * | 2010-06-10 | 2012-01-19 | Indiana University Research And Technology Corporation | Materials and method for suppressing inflamatory and neuropathic pain |
| US9629892B2 (en) * | 2010-08-12 | 2017-04-25 | Nono Inc. | Treatment of penetrative injury to the brain |
| BR112013029206B1 (pt) * | 2011-05-13 | 2021-05-04 | Kobenhavns Universitet (University Of Copenhagen) | composto, e, uso de um composto |
| KR102425466B1 (ko) | 2011-06-24 | 2022-07-25 | 노노 인코포레이티드 | 허혈에 대한 psd-95 억제제와의 조합 요법 |
| US9730921B2 (en) | 2012-03-27 | 2017-08-15 | Duke University | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| AU2013352437B2 (en) * | 2012-11-28 | 2018-04-12 | Nono Inc. | Lyophilized formulation of TAT-NR2B9c |
| US10251935B2 (en) | 2012-11-28 | 2019-04-09 | Nono Inc. | Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose |
| US9783586B2 (en) * | 2013-03-15 | 2017-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the linear ubiquitin chain assembly complex (LUBAC) and related methods |
| US20140349944A1 (en) * | 2013-05-23 | 2014-11-27 | Musc Foundation For Research Development | Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| PT2946765T (pt) | 2014-05-23 | 2016-11-10 | Ares Trading Sa | Composição farmacêutica líquida |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| WO2016049280A1 (en) * | 2014-09-24 | 2016-03-31 | Memorial Sloan Kettering Cancer Center | mTORC1 MODULATION |
| WO2019061395A1 (zh) * | 2017-09-30 | 2019-04-04 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗肽组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000034468A2 (en) * | 1998-12-11 | 2000-06-15 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US20060148711A1 (en) * | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| DE60026313D1 (de) * | 1999-07-23 | 2006-04-27 | Uutech Ltd | Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes |
| EP1210121A2 (en) * | 1999-08-24 | 2002-06-05 | Cellgate Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20020032154A1 (en) * | 2000-06-07 | 2002-03-14 | Peyman John A. | Interferon-suppressing placental lactogen peptides |
| AU2002356511A1 (en) * | 2001-07-30 | 2003-04-01 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| US20060276455A1 (en) * | 2003-02-13 | 2006-12-07 | Lindsberg Perttu J | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
| CN104558200B (zh) * | 2004-09-02 | 2021-11-16 | 康石医药科技（上海）有限公司 | 改进的apo e类似物及其使用方法 |
| US7151084B2 (en) * | 2004-12-27 | 2006-12-19 | Miller Landon C G | Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes |
| WO2009006611A1 (en) * | 2007-07-03 | 2009-01-08 | Arbor Vita Corporation | Small molecule inhibitors of pdz interactions |
| CA2694046C (en) * | 2007-07-26 | 2023-09-12 | Revance Therapeutics, Inc. | Cationic peptides and compositions thereof |
| ES2328776B1 (es) * | 2007-11-19 | 2010-07-06 | Proyecto De Biomedicina Cima S.L. | Peptidos con capacidad para unirse a escurfina y aplicaciones. |
| EP3682895A1 (en) | 2009-06-10 | 2020-07-22 | NoNO Inc. | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
-
2008
- 2008-11-26 US US12/323,915 patent/US8080518B2/en active Active
- 2008-12-02 DK DK08859906.3T patent/DK2229185T3/en active
- 2008-12-02 PT PT88599063T patent/PT2229185E/pt unknown
- 2008-12-02 ES ES08859906.3T patent/ES2555524T3/es active Active
- 2008-12-02 EP EP08859906.3A patent/EP2229185B8/en active Active
- 2008-12-02 JP JP2010537016A patent/JP5520230B2/ja active Active
- 2008-12-02 AU AU2008335490A patent/AU2008335490B2/en not_active Ceased
- 2008-12-02 PL PL08859906T patent/PL2229185T3/pl unknown
- 2008-12-02 CN CN2008801261196A patent/CN101970011B/zh active Active
- 2008-12-02 BR BRPI0820912-0A patent/BRPI0820912B1/pt active IP Right Grant
- 2008-12-02 WO PCT/US2008/085280 patent/WO2009076105A2/en active Application Filing
- 2008-12-02 SI SI200831555T patent/SI2229185T1/sl unknown
- 2008-12-02 HU HUE08859906A patent/HUE027216T2/en unknown
-
2015
- 2015-12-02 HR HRP20151312TT patent/HRP20151312T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2229185T1 (sl) | 2016-02-29 |
| JP5520230B2 (ja) | 2014-06-11 |
| PL2229185T3 (pl) | 2016-03-31 |
| JP2011506328A (ja) | 2011-03-03 |
| BRPI0820912A2 (pt) | 2018-07-17 |
| EP2229185B8 (en) | 2016-12-21 |
| AU2008335490A1 (en) | 2009-06-18 |
| HUE027216T2 (en) | 2016-08-29 |
| US8080518B2 (en) | 2011-12-20 |
| ES2555524T3 (es) | 2016-01-04 |
| BRPI0820912B1 (pt) | 2022-05-24 |
| CN101970011B (zh) | 2013-04-24 |
| WO2009076105A3 (en) | 2010-01-07 |
| AU2008335490B2 (en) | 2013-08-22 |
| US20090176713A1 (en) | 2009-07-09 |
| WO2009076105A2 (en) | 2009-06-18 |
| EP2229185A4 (en) | 2011-11-23 |
| EP2229185A2 (en) | 2010-09-22 |
| CN101970011A (zh) | 2011-02-09 |
| EP2229185B1 (en) | 2015-10-07 |
| DK2229185T3 (en) | 2016-01-11 |
| PT2229185E (pt) | 2016-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151312T1 (hr) | Ko-administracija sredstva vezanog na tat internalizacijski peptid s protuupalnim sredstvom | |
| JP2011506328A5 (hr) | ||
| EA200971130A1 (ru) | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний | |
| HRP20151148T1 (hr) | Mimotopi od alfa-sinukleina i njihova cjepiva za lijeäśenje neurodegenerativnih poremeä†aja | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| BRPI0508843A (pt) | composto ou sal do mesmo, método para preparar um composto ou um sal do mesmo, método de tratamento e/ou profilaxia de doença, e, composição farmacêutica | |
| HRP20192230T1 (hr) | Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita | |
| HRP20170531T1 (hr) | Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze | |
| JP2015522264A5 (hr) | ||
| RS51852B (sr) | Modifikovani peptidi kao terapeutski agensi | |
| EP2687220A3 (en) | Treatment of inflammatory diseases using placental stem cells | |
| HRP20140586T1 (hr) | Peptidi za lijeäśenje beta-amiloidoze | |
| WO2011157713A3 (en) | Cell-penetrating peptides and uses therof | |
| JP2014050390A5 (hr) | ||
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| JP2014514365A5 (hr) | ||
| JPWO2019156137A5 (hr) | ||
| Chou et al. | T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse | |
| JP2019513752A5 (hr) | ||
| HRP20151165T1 (hr) | Inhibitori apoptoze i njihove uporabe | |
| CN101370489A (zh) | 链烷二羧酸和类视黄醇用于治疗红斑痤疮和其它炎症性皮肤疾病的用途 | |
| HRP20160385T1 (hr) | Pripravci za prevenciju i liječenje neurodegenerativnih bolesti | |
| TWI794200B (zh) | 預防或治療免疫發炎性皮膚疾病的方法及醫藥組合物 | |
| RU2016111115A (ru) | Стабильные полипептиды, связывающиеся с с5 комплемента человека | |
| BRPI0519515A2 (pt) | uso de antagonistas de peptÍdeo liberaÇço de bombesina/gastrina para o tratamento de condiÇÕes inflamatàrias, dano de pulmço agudo e distérbio bipolar |